Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT04360005 | Managed Access Programs for ABL001, Asciminib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 5, 2025 |
| clinicaltrials |
| NCT06148506 | A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia(ValerEE) | active not recruiting | — | 376 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04745637 | Managed Access Programs for INC424, Ruxolitinib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 18, 2025 | clinicaltrials |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | terminated | Phase 1 | 154 | Novartis PharmaceuticalsINDUSTRY | 9 | Nov 14, 2025 | clinicaltrials |
| NCT05269771 | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 8 | Nov 5, 2025 | clinicaltrials |
| NCT07223476 | Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal(PORTRAIT) | completed | — | 1,926 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04838613 | Study of Diagnostic Performance of [18F]CTT1057 in BCR(GuidePath) | completed | Phase 3 | 190 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 20, 2025 | clinicaltrials |
| NCT03822468 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer(AMALEE) | completed | Phase 2 | 376 | Novartis PharmaceuticalsINDUSTRY | 23 | Oct 16, 2025 | clinicaltrials |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | terminated | Phase 1 / Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 16, 2025 | clinicaltrials |
| NCT04666259 | Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation(AIM4CML) | completed | Phase 3 | 56 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04926831 | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC(Geometry-N) | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05384587 | Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia(ASC2ESCALATE) | active not recruiting | Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 52 | Novartis PharmaceuticalsINDUSTRY | 7 | Oct 10, 2025 | clinicaltrials |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | terminated | Phase 1 | 25 | Novartis PharmaceuticalsINDUSTRY | 7 | Oct 10, 2025 | clinicaltrials |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | terminated | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 10, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | terminated | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 10, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT07188428 | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | completed | — | 2,298 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma(COMBI-i) | terminated | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 29 | Sep 18, 2025 | clinicaltrials |
| NCT04575025 | Special Drug Use-results Surveillance of Tabrecta Tablets | completed | — | 109 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07151820 | A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients | completed | — | 2,546 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07150793 | A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan | completed | — | 754 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07148505 | A Study of Real-world Outcomes Among Patients Treated With Ribociclib | completed | — | 373 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | completed | Phase 3 | 545 | Novartis PharmaceuticalsINDUSTRY | 23 | Aug 7, 2025 | clinicaltrials |
| NCT07103486 | A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | — | 264 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07086196 | A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer | completed | — | 350 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05599932 | Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07039383 | A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients(KareALL) | completed | — | 79 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT05541341 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05073120 | Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib | completed | — | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | completed | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | terminated | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | May 18, 2025 | clinicaltrials |
| NCT04237649 | KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors | terminated | Early Phase 1 | 77 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | terminated | Phase 1 | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 8 | Novartis PharmaceuticalsINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT04261439 | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | terminated | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 7 | May 6, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT04795427 | Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | completed | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT01147822 | Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 367 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials